Table 3.
Antibacterials for systemic use prescribed for therapeutic treatment, Belgian HALT surveys, 2010-2016
| J01A tetracyclines | J01B amphenicols | J01C beta-lactam antibacterials, penicillins | J01D other beta-lactam antibacterials | J01E sulfonamides and trimethoprim | J01F macrolides, lincosamides and streptogramins | J01G aminoglycoside antibacterials | J01M quinolone antibacterials | J0X other antibacterials | J01 antibacterials for systemic use Total |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||
| HALT-1 (2010) | Respiratory tract infections | 3 (2.0) | 0 (0.0) | 89 (58.6) | 6 (4.0) | 5 (3.3) | 7 (4.6) | 0 (0.0) | 42 (27.6) | 0 (0.0) | 152 (46.8) |
| Urinary tract infections | 2 (1.9) | 0 (0.0) | 2 (1.9) | 6 (5.6) | 7 (6.5) | 1 (0.9) | 0 (0.0) | 38 (35.2) | 52 (48.2) | 108 (33.2) | |
| Skin or wound infections | 4 (9.1) | 0 (0.0) | 23 (52.3) | 2 (4.6) | 2 (4.6) | 4 (9.1) | 0 (0.0) | 9 (20.5) | 0 (0.0) | 44 (13.5) | |
| All infection groups | 10 (3.1) | 0 (0.0) | 123 (37.9) | 14 (4.3) | 14 (4.3) | 15 (4.6) | 0 (0.0) | 96 (29.5) | 53 (16.3) | 325 (100.0) | |
| HALT-2 (2013) | Respiratory tract infections | 1 (0.9) | 0 (0.0) | 65 (56.0) | 5 (4.3) | 1 (0.9) | 17 (14.7) | 0 (0.0) | 27 (23.3) | 0 (0.0) | 116 (42.5) |
| Urinary tract infections | 0 (0.0) | 0 (0.0) | 9 (9.2) | 3 (3.1) | 5 (5.1) | 1 (1.0) | 0 (0.0) | 27 (27.6) | 53 (54.1) | 98 (35.9) | |
| Skin or wound infections | 2 (5.7) | 0 (0.0) | 20 (57.1) | 1 (2.9) | 2 (5.7) | 3 (8.6) | 0 (0.0) | 7 (20.0) | 0 (0.0) | 35 (12.8) | |
| All infection groups | 3 (1.1) | 0 (0.0) | 105 (38.5) | 9 (3.3) | 9 (3.3) | 23 (8.4) | 0 (0.0) | 68 (24.9) | 56 (20.5) | 273 (100.0) | |
| HALT-3 (2016) | Respiratory tract infections | 4 (1.6) | 1 (0.4) | 137 (55.5) | 12 (4.9) | 4 (1.6) | 34 (13.8) | 0 (0.0) | 55 (22.3) | 0 (0.0) | 247 (44.9) |
| Urinary tract infections | 0 (0.0) | 0 (0.0) | 26 (12.8) | 4 (2.0) | 9 (4.4) | 1 (0.5) | 0 (0.0) | 61 (29.9) | 103 (50.5) | 204 (37.1) | |
| Skin or wound infections | 5 (9.1) | 0 (0.0) | 31 (56.4) | 1 (1.8) | 3 (5.5) | 5 (10.9) | 1 (1.8) | 6 (10.9) | 2 (3.6) | 55 (10.0) | |
| All infection groups | 13 (2.4) | 1 (0.2) | 210 (38.2) | 20 (3.6) | 19 (3.5) | 50 (9.1) | 1 (0.2) | 130 (23.6) | 106 (19.3) | 550 (100.0) |
Antimicrobials presented according to the Anatomical Therapeutic Chemical (ATC) classification system level 3 subclasses; no J01R combinations were reported